Dazucorilant failed to slow disease progression in ALS patients in the DAZALS Phase 2 clinical trial, but may have extended ...

The experimental therapy Bravyl significantly reduced the spread of toxic TDP-43 protein clumps in a cell model of ALS.

A new meta-analysis suggests that active exercise may slow functional decline in ALS, while noninvasive brain stimulation ...

In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...

Researchers from the Structural Biology Brussels group at Vrije Universiteit Brussel (VUB) have uncovered a significant ...

Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

A new study from the Institute of Environmental Medicine (IMM), published in The Lancet Regional Health - Europe, shows that ...

A promising ultrasound therapy to potentially restore brain function in people with Alzheimer's disease has been licenced to ...

VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces ...

Pleiotropic loci that play a role in multiple neuropsychiatric diseases exist, but many of them might contribute to each disease via a distinct mechanism.